181 related articles for article (PubMed ID: 18392754)
1. Increased efficacy of micro-opioid agonist-induced antinociception by metabotropic glutamate receptor antagonists in C57BL/6 mice: comparison with (-)-6-phosphonomethyl-deca-hydroisoquinoline-3-carboxylic acid (LY235959).
Fischer BD; Miller LL; Henry FE; Picker MJ; Dykstra LA
Psychopharmacology (Berl); 2008 Jun; 198(2):271-8. PubMed ID: 18392754
[TBL] [Abstract][Full Text] [Related]
2. Attenuation of mu-opioid tolerance and cross-tolerance by the competitive N-methyl-D-aspartate receptor antagonist LY235959 is related to tolerance and cross-tolerance magnitude.
Allen RM; Dykstra LA
J Pharmacol Exp Ther; 2000 Dec; 295(3):1012-21. PubMed ID: 11082436
[TBL] [Abstract][Full Text] [Related]
3. Interactions between an N-methyl-D-aspartate antagonist and low-efficacy opioid receptor agonists in assays of schedule-controlled responding and thermal nociception.
Fischer BD; Dykstra LA
J Pharmacol Exp Ther; 2006 Sep; 318(3):1300-6. PubMed ID: 16772537
[TBL] [Abstract][Full Text] [Related]
4. Effects of N-methyl-D-aspartate receptor antagonists on acute morphine-induced and l-methadone-induced antinociception in mice.
Fischer BD; Carrigan KA; Dykstra LA
J Pain; 2005 Jul; 6(7):425-33. PubMed ID: 15993820
[TBL] [Abstract][Full Text] [Related]
5. The competitive N-methyl-D-aspartate receptor antagonist (-)-6-phosphonomethyl-deca-hydroisoquinoline-3-carboxylic acid (LY235959) potentiates the antinociceptive effects of opioids that vary in efficacy at the mu-opioid receptor.
Allen RM; Granger AL; Dykstra LA
J Pharmacol Exp Ther; 2003 Nov; 307(2):785-92. PubMed ID: 12975489
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of MPEP, an mGluR5 antagonist, and memantine, an N-methyl-D-aspartate receptor antagonist, on morphine antinociceptive tolerance in mice.
Kozela E; Pilc A; Popik P
Psychopharmacology (Berl); 2003 Jan; 165(3):245-51. PubMed ID: 12442203
[TBL] [Abstract][Full Text] [Related]
7. Attenuation of morphine antinociceptive tolerance by a CB(1) receptor agonist and an NMDA receptor antagonist: Interactive effects.
Fischer BD; Ward SJ; Henry FE; Dykstra LA
Neuropharmacology; 2010 Feb; 58(2):544-50. PubMed ID: 19699755
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological Characterization of Dezocine, a Potent Analgesic Acting as a κ Partial Agonist and μ Partial Agonist.
Wang YH; Chai JR; Xu XJ; Ye RF; Zan GY; Liu GY; Long JD; Ma Y; Huang X; Xiao ZC; Dong H; Wang YJ
Sci Rep; 2018 Sep; 8(1):14087. PubMed ID: 30237513
[TBL] [Abstract][Full Text] [Related]
9. Opioid antinociception, tolerance and dependence: interactions with the N-methyl-D-aspartate system in mice.
Dykstra LA; Fischer BD; Balter RE; Henry FE; Schmidt KT; Miller LL
Behav Pharmacol; 2011 Sep; 22(5-6):540-7. PubMed ID: 21712708
[TBL] [Abstract][Full Text] [Related]
10. Competitive and non-competitive NMDA antagonists block the development of antinociceptive tolerance to morphine, but not to selective mu or delta opioid agonists in mice.
Bilsky EJ; Inturrisi CE; Sadée W; Hruby VJ; Porreca F
Pain; 1996 Dec; 68(2-3):229-37. PubMed ID: 9121809
[TBL] [Abstract][Full Text] [Related]
11. N-methyl-D-aspartate receptor antagonists potentiate the antinociceptive effects of morphine in squirrel monkeys.
Allen RM; Dykstra LA
J Pharmacol Exp Ther; 2001 Jul; 298(1):288-97. PubMed ID: 11408554
[TBL] [Abstract][Full Text] [Related]
12. Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors.
Lutfy K; Eitan S; Bryant CD; Yang YC; Saliminejad N; Walwyn W; Kieffer BL; Takeshima H; Carroll FI; Maidment NT; Evans CJ
J Neurosci; 2003 Nov; 23(32):10331-7. PubMed ID: 14614092
[TBL] [Abstract][Full Text] [Related]
13. Sex-related differences in the antinociceptive effects of opioids: importance of rat genotype, nociceptive stimulus intensity, and efficacy at the mu opioid receptor.
Cook CD; Barrett AC; Roach EL; Bowman JR; Picker MJ
Psychopharmacology (Berl); 2000 Jul; 150(4):430-42. PubMed ID: 10958085
[TBL] [Abstract][Full Text] [Related]
14. Antinociceptive effects and synergistic interaction with morphine of intrathecal metabotropic glutamate receptor 2/3 antagonist in the formalin test of rats.
Yoon MH; Choi Jl; Bae HB; Kim SJ; Chung ST; Jeong SW; Chung SS; Yoo KY; Jeong CY
Neurosci Lett; 2006 Feb; 394(3):222-6. PubMed ID: 16293369
[TBL] [Abstract][Full Text] [Related]
15. Discriminative stimulus effects of the mixed-opioid agonist/antagonist dezocine: cross-substitution by mu and delta opioid agonists.
Picker MJ
J Pharmacol Exp Ther; 1997 Dec; 283(3):1009-17. PubMed ID: 9399970
[TBL] [Abstract][Full Text] [Related]
16. An examination of the interactions between the antinociceptive effects of morphine and various mu-opioids: the role of intrinsic efficacy and stimulus intensity.
Morgan D; Cook CD; Smith MA; Picker MJ
Anesth Analg; 1999 Feb; 88(2):407-13. PubMed ID: 9972766
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of dezocine, pentazocine and tapentadol on antinociception and physical dependence.
Ahsan MZ; Zhao MJ; Shoaib RM; Zhang Y; Wang YX
Life Sci; 2021 Nov; 285():119996. PubMed ID: 34597607
[TBL] [Abstract][Full Text] [Related]
18. Morphine in combination with metabotropic glutamate receptor antagonists on schedule-controlled responding and thermal nociception.
Fischer BD; Zimmerman EI; Picker MJ; Dykstra LA
J Pharmacol Exp Ther; 2008 Feb; 324(2):732-9. PubMed ID: 17982001
[TBL] [Abstract][Full Text] [Related]
19. Potency differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid micro-agonists in an antinociception assay.
Sterious SN; Walker EA
J Pharmacol Exp Ther; 2003 Jan; 304(1):301-9. PubMed ID: 12490605
[TBL] [Abstract][Full Text] [Related]
20. Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in mu-opioid receptor knockout mice.
Ide S; Minami M; Satoh M; Uhl GR; Sora I; Ikeda K
Neuropsychopharmacology; 2004 Sep; 29(9):1656-63. PubMed ID: 15100703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
